A Study of S-606001 as Monotherapy in Participants With Late-onset Pompe Disease (LOPD)
← catalyst calendarNCT07787650 · readout in 796 d
Sponsored by Shionogi (industry) · 4507.T — their whole pipeline →.
Phase
Phase 1
Status
Not yet recruiting
Study type
Interventional
Design
Na · None · Treatment
Enrollment
15estimated
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-26
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-09-30 | estimated | When the study began enrolling |
| Primary completion | 2028-10-31 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-10-31 | estimated | The whole study's end, after follow-up |
| First posted | 2026-08-26 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-26 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Pompe Disease
Intervention
- Drug: S-606001
Primary outcome
what the primary-completion date above is the date OFNumber of Participants with Treatment-emergent Adverse Events
measured Baseline (Day 1) through Week 49
Related
4507.T's other studiesmost recently updated first
- A Study of Secutrelvir in Participants With Coronavirus Disease 2019 (COVID-19) Who Are at High Risk for Progression to Severe Disease Phase 3 · Recruiting
- Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS Phase 3 · Terminated
- A Study to Compare S-217622 With Placebo in Non-Hospitalized Participants With COVID-19 Phase 3 · Completed
- A Study of S-337395 in Symptomatic Nonhospitalized Adults With Respiratory Syncytial Virus (RSV) Who Are at High Risk of Progression to Severe Disease Phase 2 · Recruiting
- An Extension Study of S-606001 in Participants With Late-onset Pompe Disease (LOPD) Phase 2 · Not yet recruiting
Permalink · 4507.T's whole pipeline · Catalyst calendar · Every registered study · What changed